For millions considering or using glucagon-like peptide-1 receptor agonists (GLP-1s) for weight management, the choice between pills and injections is now a reality. The U.S. Food and Drug Administration (FDA) recently approved oral semaglutide (Wegovy) for weight loss, and more options are in development. This shift matters because it removes a significant barrier to entry for many: the need for weekly injections.
Why Oral GLP-1s Were a Challenge
Historically, delivering GLP-1s orally has been difficult. The active peptides in these medications are easily broken down by stomach acid and digestive enzymes before the body can absorb them. Newer oral formulations are engineered to protect these peptides, ensuring they survive the digestive process. The key difference? Higher doses are needed to achieve the same effect as injections.
Weight Loss: Pills vs. Shots
Clinical trials show that the oral semaglutide (Wegovy) pill delivers comparable weight loss results to its injectable counterpart. In one FDA-reviewed trial, adults taking 25 milligrams (mg) daily lost an average of 13.6% of their body weight over 64 weeks, compared to just 2.2% in a placebo group. Weekly injections of 2.4 mg semaglutide resulted in an average loss of 14.9% over 68 weeks, with the placebo group losing 2.4%.
The higher pill dosage (25 mg vs. 2.4 mg injection) is necessary because the drug’s absorption into the bloodstream is naturally lower when taken orally. As Dr. W. Timothy Garvey explains, “The amount of medication entering the bloodstream is similar for the oral and injectable, but the absorption process is less efficient.”
Beyond Weight: Additional Benefits
Both pill and injectable forms of semaglutide offer secondary health benefits. They lead to modest improvements in blood sugar control (around -0.2% to -0.3% A1C reduction) and cholesterol levels (around -2% to -3% total cholesterol reduction). The FDA has also approved the pill for secondary prevention of major cardiovascular events in overweight or obese patients with existing heart disease, though approval for liver disease (MASH) is still pending. Early studies suggest the pill may also benefit liver health, but more research is needed.
Notably, these medications affect the brain’s reward centers related to overeating, helping to reduce food cravings and intrusive thoughts.
Side Effects: What to Expect
Side effects are largely similar for both forms. The most common include mild to moderate gastrointestinal (GI) issues. In trials, approximately 46.6% of pill takers and 44% of injection users experienced nausea, while diarrhea and vomiting rates were 17.6% and 30.9% for the pill versus 32% and 25% for injections.
The specific timing of nausea may differ between the two methods, with some injection users reporting more nausea on days two and three after the shot. More data is needed to confirm if this is a consistent pattern.
What’s Next: Other Oral GLP-1s in Development
Wegovy is just the first oral GLP-1 approved for weight management. Several other drugs are in late-stage trials:
- Orforglipron (Eli Lilly): This small-molecule drug may reduce dietary restrictions due to its better absorption. Phase 3 trials showed an average weight loss of 12.4% over 72 weeks. The FDA is expected to make a decision in the second quarter of 2026.
- Aleniglipron (Structure Therapeutics): Another small-molecule drug, this one demonstrated an average weight loss of 14.2% over 36 weeks in phase 2b trials.
- Amycretin (Novo Nordisk): This experimental drug targets two hormones (GLP-1 and amylin) and showed a mean weight loss of 13% after just 12 weeks in phase 1 trials.
The Bottom Line
Research shows that oral GLP-1s deliver comparable weight loss to injectable medications, with similar health benefits and side effects. The primary difference remains convenience: pills require daily intake with dietary restrictions, while injections are weekly. However, ongoing research is paving the way for future oral formulations with fewer dietary limitations.
Ultimately, the choice depends on individual preference and tolerance for dietary changes versus injection frequency.
